^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Eye Cancer

1d
Selective Induction of Intrinsic Apoptosis in Retinoblastoma Cells by Novel Cationic Antimicrobial Dodecapeptides. (PubMed, Pharmaceutics)
Combining HC3 or HC5 with the standard chemotherapeutic drug topotecan showed synergistic anti-cancer activities. Overall, these results suggest that HC3 and HC5 can be exploited as potential therapeutic agents in retinoblastoma as monotherapy or as adjunctive therapy to enhance the effectiveness of currently used treatment modalities.
Journal
|
RB1 (RB Transcriptional Corepressor 1) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
topotecan
4d
KTN1-AS1, a SOX2-mediated lncRNA, activates epithelial-mesenchymal transition process in esophageal squamous cell carcinoma. (PubMed, Sci Rep)
Furthermore, KTN1-AS1 could bind to retinoblastoma binding protein 4 (RBBP4) in the nucleus and enhanced its binding with histone deacetylase 1 (HDAC1), thereby activating the epithelial-mesenchymal transition (EMT) process through downregulating E-cadherin expression at the epigenetic level. In conclusion, KTN1-AS1, induced by SOX2, acts as a tumor-promoting gene and may serve as a potential therapeutic and prognostic biomarker for ESCC.
Journal
|
CDH1 (Cadherin 1) • SOX2 • HDAC1 (Histone Deacetylase 1) • NECTIN1 (Nectin Cell Adhesion Molecule 1)
|
CDH1 expression
6d
Likelihood of germline mutation with solitary retinoblastoma based on tumour location at presentation. (PubMed, Br J Ophthalmol)
Among patients with solitary unilateral retinoblastoma, those presenting with macular tumour (compared with extramacular tumour) show 2.18 times greater likelihood for germline mutation and an even higher likelihood of development of subsequent tumours. Solitary macular retinoblastoma should raise an index of suspicion for likely germline mutation and multifocal disease.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
|
RB1 mutation
7d
Retinoblastoma: Review and new insights. (PubMed, Front Oncol)
Rb can be detected by the Bruckner test showing a pupil that shines white or "Leukocoria". Although the diagnosis of Rb remains essentially clinical, the newly identified biomarkers could contribute to early molecular detection, timely detection of micrometastases and establish new therapeutic options for Rb.
Review • Journal
|
RB1 (RB Transcriptional Corepressor 1)
10d
Retinoblastoma expression and targeting by CDK4/6 inhibitors in small cell lung cancer. (PubMed, Mol Cancer Ther)
SCLC cells and xenograft tumors with RB1 protein expression were sensitive to growth inhibition by the CDK4/6 inhibitor palbociclib, and this inhibition was shown to be dependent on RB1 expression by CRISPR knockout. Finally, we identified a transcriptomics-based RB1 loss-of-function signature that discriminates between SCLC cells with or without RB1 protein expression and validated it in the patient who was responsive to abemaciclib, suggesting its potential use to predict CDK4/6 inhibitor response in SCLC patients. Our study demonstrates that RB1 protein is an actionable target in a subgroup of SCLC, a cancer that exhibits no currently targetable mutations.
Journal
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • YAP1 (Yes associated protein 1)
|
TP53 mutation • RB1 mutation • RB1 expression
|
Ibrance (palbociclib) • Verzenio (abemaciclib)
10d
A miRNA-based gene therapy nanodrug synergistically enhances pro-inflammatory antitumor immunity against melanoma. (PubMed, Acta Biomater)
• The rMMNs promoted M1 macrophage polarization thus synergistically enhancing pro-inflammatory anti-tumor immunity against melanoma. • The rMMNs showed no obvious toxicity under the injection dose.
Journal
|
E2F7 (E2F Transcription Factor 7) • MIR30A (MicroRNA 30a)
10d
The clinical diagnostic value of plasma miR-592 and miR-217-3p levels in retinoblastoma. (PubMed, J Med Biochem)
The high expression of miR-592 and miR-217-3p presents a more serious pathological manifestation of Rb, and the overall survival of patients is significantly shortened with the increase of miR-592 (r=-0.2276, p=0.0052) and miR-217-3p levels (r=-0.6461, p 0.0001). and miR-217-3p are highly expressed in the plasma of Rb patients, and their elevated levels present severe pathological manifestations of Rb and shortened overall survival, which is expected to become biomarkers for clinical diagnosis of Rb.
Journal
|
MIR217 (MicroRNA 217)
11d
LPCAT3 is a potential prognostic biomarker and may be correlated with immune infiltration and ferroptosis in acute myeloid leukemia: a pan-cancer analysis. (PubMed, Transl Cancer Res)
In addition, the result of prediction drug response suggested that B-cell lymphoma 2 (BCL2) inhibitors and Midostaurin may be a potential treatment option for AML with low-LPCAT3 expression...Overexpression of LPCAT3 is associated with poor prognosis and tumor immune microenvironment in many cancers, especially in AML. Our results showed that the oncogene of LPCAT3 may serve as a potential prognostic biomarker and/or therapeutic target in AML patients.
Journal • Tumor Mutational Burden • IO biomarker • Pan tumor
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
Rydapt (midostaurin)
12d
Embryonal tumors with multilayered rosettes, C19MC-altered or not elsewhere classified: Clinicopathological characteristics, prognostic factors, and outcomes of 17 children from 2018 to 2022. (PubMed, Front Oncol)
Chemotherapy is the only prognostic factor for ETMRs patients with a favorable prognosis. The biological nature and clinical patterns for recurrent diseases need to be further demonstrated to predict prognosis and guide treatment.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
12d
Doxorubicin-Loaded Extracellular Vesicles Enhance Tumor Cell Death in Retinoblastoma. (PubMed, Bioengineering (Basel))
Direct interaction of EV membrane moieties with retinoblastoma cell surface receptors resulted in an effective drug delivery to cancer cells. Our findings emphasize the intriguing potential of EVs as optimum methods for delivering Dox to retinoblastoma.
Journal
|
CASP3 (Caspase 3) • CASP7 (Caspase 7)
13d
Clinical significance of serum and vitreous soluble interleukin-2 receptor in patients with intraocular lymphoma. (PubMed, BMC Ophthalmol)
Serum sIL-2R is often within the normal range in IOL patients. Even if it is within the normal range, the possibility of IOL should be considered. Serum sIL-2R is not a reliable biomarker for IOL, whereas vitreous sIL-2R may be useful for the diagnosis of IOL.
Journal
|
IL2 (Interleukin 2) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
13d
Proteomics of Aqueous Humor as a Source of Disease Biomarkers in Retinoblastoma. (PubMed, Int J Mol Sci)
Our results provide a proteome database regarding AH related to RB disease that may be used as a source of biomarkers. Further prospective studies should validate our finding in a large cohort of RB patients.
Journal
|
GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)
|
CD44 expression
13d
Diagnostic Accuracy of Vitreous Cytology in Patients with Vitreoretinal Lymphoma. (PubMed, J Clin Med)
(4) The VRL detection rate for vitreous cytology was lower than that for the other tests, especially in patients who received steroid pretreatment. These findings suggest that even if vitreous cytology findings are negative, other tests and characteristic fundus findings should be evaluated to confirm VRL diagnosis.
Journal
|
IGH (Immunoglobulin Heavy Locus) • IL10 (Interleukin 10) • IL6R (Interleukin 6 receptor)
13d
Impact of TMPRSS2 Expression, Mutation Prognostics, and Small Molecule (CD, AD, TQ, and TQFL12) Inhibition on Pan-Cancer Tumors and Susceptibility to SARS-CoV-2. (PubMed, Molecules)
Cancer cell lines were treated with small molecules, including cordycepin (CD), adenosine (AD), thymoquinone (TQ), and TQFL12, to mediate TMPRSS2 expression. Notably, CD, AD, TQ, and TQFL12 inhibited TMPRSS2 expression in cancer cell lines, including the PC3 prostate cancer cell line, implying a therapeutic role for preventing COVID-19 in cancer patients. Together, these findings are the first to demonstrate that small molecules, such as CD, AD, TQ, and TQFL12, inhibit TMPRSS2 expression, providing novel therapeutic strategies for preventing COVID-19 and cancers.
Journal • BRCA Biomarker • Pan tumor
|
BRCA (Breast cancer early onset) • TMPRSS2 (Transmembrane serine protease 2)
|
cordycepin (OVI-123)
14d
IL-6 evoked biochemical changes in prostate cancer cells. (PubMed, Cytokine)
In LNCaP cells, IL-6 acting alone or together with FSK had no effect on the expression of several biological markers of advanced PCa, including Aurora kinase A, valosin-containing protein, calcium-sensing receptor, calreticulin, S100A protein, and Protein S. In PC3 cells, co-treatment with IL-6 + FSK evoked increased expression of REST and S100A proteins, as well as a reduction in Protein S levels. These findings reveal a complex pattern of biochemical changes in PCa cells under the influence of IL-6.
Journal
|
RB1 (RB Transcriptional Corepressor 1) • IL6 (Interleukin 6) • AURKA (Aurora kinase A) • CALR (Calreticulin) • NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1)
|
IL6 expression
14d
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (clinicaltrials.gov)
P1/2, N=124, Recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
Trial completion date • Trial primary completion date
|
GNAQ (G Protein Subunit Alpha Q)
|
DYP688
15d
A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors. (PubMed, Sci Rep)
HK2 expression was associated with the infiltration of T follicular helper cells for the TCGA tumors of uveal melanoma, breast invasive carcinoma (BRCA), breast invasive carcinoma-luminalA (BRCA-LumA), head and neck squamous cell carcinoma (HNSC), head and neck squamous cell carcinoma with HPV positive (HNSC-HPV), and cancer-associated fibroblasts for the tumors of brain lower grade glioma and stomach adenocarcinoma. Our first pan-cancer study offers a relatively comprehensive understanding of the roles of HK2 in different tumors.
Journal • BRCA Biomarker • Pan tumor
|
BRCA (Breast cancer early onset)
15d
Targeted OUM1/PTPRZ1 silencing and synergetic CDT/enhanced chemical therapy toward uveal melanoma based on a dual-modal imaging-guided manganese metal-organic framework nanoparticles. (PubMed, J Nanobiotechnology)
Hence, siRNAs that selectively knocking down the lncRNA OUM1 (siOUM1) and its target gene PTPRZ1 (siPTPRZ1) were designed to inhibit the OUM1/PTPRZ1 pathway to reduce PTP activity, and this reduction in activity interrupts protein tyrosine phosphorylation, suppresses UM proliferation and metastasis and improves cisplatin sensitivity in UM cells...This NP system also has a dual-modal imaging ability because ICG is a near-infrared region fluorescent dye and manganese has the potential to be used in magnetic resonance imaging. This study verifies the significance of the newly discovered lncRNA OUM1 as a new therapeutic target for aggressive UM and provides a drug delivery NP system for precise treatment of UM accompanied with a dual-modal imaging ability.
Journal
|
PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)
|
cisplatin
21d
Methylation-driven gene DLL3 is a potential prognostic biomarker in ocular melanoma correlating with metastasis. (PubMed, Front Oncol)
Methylation-driven gene DLL3 could serve as a new potential diagnostic and prognostic biomarker in ocular melanoma. Our findings may contribute to improving the clinical outcomes of patients with UM or CM.
Journal
|
DLL3 (Delta Like Canonical Notch Ligand 3)
|
DLL3 expression
21d
Reconstruct Human Retinoblastoma In Vitro. (PubMed, J Vis Exp)
Altogether, by differentiating the gene-edited hESC lines into the retinal organoids using a 2D and 3D combined differentiation protocol, we have successfully reconstructed the human RB in a dish and identified its cone-precursor origin. It would provide a helpful disease model for observing the retinoblastoma genesis, proliferation, and growth as well as further developing novel therapeutic agents.
Preclinical • Journal
|
RB1 (RB Transcriptional Corepressor 1)
|
RB1 mutation
21d
Chromosome 6p amplification detected in blood cell-free DNA in advanced intraocular retinoblastoma. (PubMed, Ophthalmic Genet)
To our knowledge, this is the first time an SCNA has been detected in the blood of an RB patient, suggesting in some advanced eyes there may be a high enough tumor fraction to detect these alterations (>5% needed). It remains unclear whether 6p gain or increased tumor fraction in the blood is indicative of increased risk of metastatic disease or new primary cancer; studies to address this are ongoing.
Journal
|
RB1 (RB Transcriptional Corepressor 1) • APC (APC Regulator Of WNT Signaling Pathway)
|
RB1 mutation • Chr amplification(6p)
21d
Rb1 negatively regulates bone formation and remodeling through inhibiting transcriptional regulation of YAP in Glut1 and OPG expression and glucose metabolism in male mice. (PubMed, Mol Metab)
Collectively, these findings demonstrated that Rb1 in MSCs inhibits YAP-medicated Glut1 and OPG expression to control glucose metabolism, osteogenesis and osteoclastogenesis during bone formation and remodeling, which provide new insights that controlling Rb1 signaling may be a potential strategy for osteopetrosis.
Preclinical • Journal
|
RB1 (RB Transcriptional Corepressor 1)
|
RB1 mutation • RB1 negative
24d
PRMT5 promotes retinoblastoma development. (PubMed, Hum Cell)
Further silencing of VEGFA in RB cells overexpressing PRMT5 constrained the expression of MMP1, MMP2 and MMP9, and suppressed the growth of tumors in mice. In conclusion, this study clarifies that the depletion of PRMT5 reduces H3K4me3-mediated VEGFA transcription and retards the carcinogenesis of RB by suppressing the expression of MMPs.
Journal
|
MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • PRMT5 (Protein Arginine Methyltransferase 5) • MMP1 (Matrix metallopeptidase 1)
|
PRMT5 overexpression
25d
Cytidine analogs are synthetic lethal with base excision repair default due to MBD4 deficiency. (PubMed, NPJ Precis Oncol)
We further confirm the exquisite activity of gemcitabine in an MBD4-deficient co-clinical model as (i) it completely prevented the development of an MBD4-deficient uveal melanoma patient-derived xenograft and (ii) treatment in the corresponding patient resulted in an exceptional tumor response. These data suggest that patients harboring MBD4-deficient tumors may be treated efficiently by cytidine analogs.
Journal • Synthetic lethality
|
MBD4 (Methyl-CpG Binding Domain 4, DNA Glycosylase)
|
MBD4 mutation
|
gemcitabine
25d
MDM2-p53 Inhibitor Alrizomadlin (APG-115) Enhances Antitumor Activity of Pomalidomide in Multiple Myeloma (MM) (ASH 2022)
Conclusions Preclinical research suggests that MDM2 inhibitor alrizomadlin in combination with pomalidomide has synergistic antitumor effects in MM tumors harboring TP53WT. These findings support further clinical evaluation of this novel combination for patients with relapsed/refractory MM.
PARP Biomarker • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CRBN (Cereblon) • IKZF1 (IKAROS Family Zinc Finger 1) • BCL2L11 (BCL2 Like 11) • IKZF3 (IKAROS Family Zinc Finger 3) • CASP3 (Caspase 3) • IRF4 (Interferon regulatory factor 4) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
TP53 wild-type • MYC expression • TP53 expression • IRF4 expression
|
pomalidomide • alrizomadlin (APG-115)
25d
Elucidating the Molecular Mechanisms of Action of CC-99282, a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent, Via Genome-Wide CRISPR Screen in a Preclinical Model of Non-Hodgkin Lymphoma (NHL) (ASH 2022)
Compared with immunomodulatory agents such as lenalidomide that also degrade Ikaros/Aiolos, CC-99282 demonstrates a faster, deeper, and more sustained degradation of these transcription factors...Venetoclax (VEN), a BCL2 inhibitor approved for the treatment of pts with chronic lymphocytic leukemia and acute myeloid leukemia, was tested in aggressive NHL cell lines alone or in combination with CC-99282...Lastly, combination of CC-99282 with CDK4/6 inhibitors palbociclib/abemaciclib, which prevent cell-cycle progression, showed strong synergistic effects in NHL cell lines without RB1 loss or CCND3 mutations...This study revealed genetic alterations that may be associated with clinical response to CC-99282 in pts with NHL. These in vitro data highlight potential biomarkers that could facilitate patient stratification in future clinical trials and provide rationale for combination therapies that may improve clinical outcomes for pts with R/R NHL.
Preclinical • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • RB1 (RB Transcriptional Corepressor 1) • BCL6 (B-cell CLL/lymphoma 6) • CRBN (Cereblon) • IKZF1 (IKAROS Family Zinc Finger 1) • CCND3 (Cyclin D3) • DDB1 (Damage Specific DNA Binding Protein 1) • AMBRA1 (Autophagy And Beclin 1 Regulator 1) • BECN1 (Beclin 1) • IRF7 (Interferon Regulatory Factor 7)
|
BCL2 expression • BCL2 translocation
|
Venclexta (venetoclax) • Ibrance (palbociclib) • lenalidomide • Verzenio (abemaciclib) • CC-99282
25d
A Comprehensive Pan-Cancer Analysis of the Tumorigenic Effect of Leucine-Zipper-Like Transcription Regulator (LZTR1) in Human Cancer. (PubMed, Oxid Med Cell Longev)
Finally, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Body (GO) method was used to explain the pathogenesis of LZTR1. Our pan-cancer study provides a relatively comprehensive understanding of the carcinogenic role of LZTR1 in human tumors.
Journal • Pan tumor
|
CD8 (cluster of differentiation 8) • LZTR1 (Leucine Zipper Like Transcription Regulator 1)
25d
Analysis of progress characteristics of retinoblastoma based on single cell transcriptome sequencing (PubMed, Sheng Wu Gong Cheng Xue Bao)
Meanwhile, the results of differential analysis of microglial populations during RB progression showed that the key genes mainly involved in immune response include RPL23, B2M, and HLA superfamily genes. This study provides new perspectives and data resources for the research of RB pathogenesis and progress.
Journal
|
B2M (Beta-2-microglobulin) • RPL23 (Ribosomal Protein L23)
25d
Targeted long-read sequencing allows for rapid identification of pathogenic disease-causing variants in retinoblastoma. (PubMed, Ophthalmic Genet)
Application of this for the first time in a retinoblastoma patient allowed haplotagged variant identification and demonstrated excellent concordance with benchmark short-read sequencing. The added benefit of targeted long-read sequencing to resolve disease-causing genomic variation in RB1 rapidly from a blood draw will provide a more definitive diagnosis of heritable RB and guide management decisions for patients and their families.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
25d
Atypical anterior retinoblastoma: diagnosis by aqueous humor cell-free DNA analysis. (PubMed, Ophthalmic Genet)
Partial regression followed three cycles of systemic carboplatin, etoposide, and vincristine and three intracameral melphalan injections. Four months later, she had recurrence of the primary tumor and increase in seeding and received the investigational sustained release episcleral topotecan chemoplaque. Stable regression was achieved to 28-month follow-up, with no detectable aqueous cell-free DNA. RB1 sequencing analysis of tumor-derived cell-free DNA from aqueous humor can confirm the diagnosis of retinoblastoma in cases of diagnostic uncertainty.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
|
RB1 deletion
|
carboplatin • etoposide IV • vincristine • topotecan • melphalan • topotecan episcleral
25d
Interleukin-11 (IL11) inhibits myogenic differentiation of C2C12 cells through activation of extracellular signal-regulated kinase (ERK). (PubMed, Cell Signal)
However, only ERK inhibitors including PD98059 and U0126 were able to ameliorate the suppressive effect of IL11 on the expression of MHC and myogenin...Together, our results suggest that IL11 inhibits myogenic differentiation through delayed cell cycle exit in an ERK-dependent manner. To our knowledge, this study is the first to demonstrate an inhibitory role of IL11 in myogenic differentiation and identifies the previously unrecognized role of IL11 as a possible mediator of CAC.
Journal
|
IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
PD98059
25d
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases (clinicaltrials.gov)
P1, N=27, Active, not recruiting, Emory University | Trial completion date: Oct 2022 --> Oct 2023
Trial completion date
|
BRAF (B-raf proto-oncogene) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • CD8 (cluster of differentiation 8) • CD14
|
Keytruda (pembrolizumab)
27d
Combination of ribociclib with BET-bromodomain and PI3K/mTOR inhibitors for medulloblastoma treatment in vitro and in vivo. (PubMed, Mol Cancer Ther)
A reverse combination screen using the BET inhibitor JQ1 as anchor, revealed CDK4/6i as the most potentiating drugs...Despite in vitro synergy, combination of ribociclib with the PI3K/mTOR inhibitor paxalisib did not significantly improve the survival of G3 and SHH MB bearing mice compared to ribociclib alone...Importantly, in one untreated Group3 medulloblastoma model HD-MB03, the PI3K/AKT/MTORC1 gene set was enriched in vitro compared to in vivo suggesting that the pathway displayed increased activity in vitro. Our data illustrate the difficulty in translating in vitro findings in vivo.
Preclinical • Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
Kisqali (ribociclib) • JQ-1 • paxalisib (GDC-0084)
27d
The prognostic implication of latitude in uveal melanoma: a nationwide observational cohort study of all patients born in Sweden between 1947 and 1989. (PubMed, Discov Oncol)
Latitude is a prognostic factor in uveal melanoma. This does not seem to be related to variations in patient or tumor characteristics at presentation, in management, in sunlight intensity, in ultraviolet light irradiance, in temperature, or in wealth. Future studies should examine if periodical changes in daylight hours or other factors could explain the prognostic implication.
Observational data • Journal
|
BAP1 (BRCA1 Associated Protein 1)
28d
miR-20b-5p is a novel biomarker for detecting prostate cancer. (PubMed, Oncol Lett)
In conclusion, the present study demonstrated that miR-20b-5p was upregulated in PCa at the tissue and cellular levels, as well as in prostatic fluid exosomes. Therefore, miR-20b-5p may be a promising early diagnostic biomarker for PCa and an important tool to guide the decision-making of prostate biopsy.
Journal
|
RB1 (RB Transcriptional Corepressor 1) • MIR20B (MicroRNA 20b)
|
miR-20b-5p expression
28d
Dysregulation of B7 family and its association with tumor microenvironment in uveal melanoma. (PubMed, Front Immunol)
Dysregulation of the B7 family in UVM is associated with poor prognosis and affects the tumor immune microenvironment. CABP4 and RORB can serve as potential therapeutic targets for UVM, which can be regulated by the B7 family to affect the visual perception and immune response function of the eye, thus influencing the prognosis of UVM.
Journal
|
CD8 (cluster of differentiation 8) • HLA-C (Major Histocompatibility Complex, Class I, C)
1m
Actualities in the Morphology and Immunohistochemistry of Cutaneous and Ocular Melanoma: What Lies Ahead? A Single-Centre Study. (PubMed, Biomedicines)
Melanoma can appear in various forms, and sometimes the diagnosis might be unclear. Today, immunohistochemistry remains the most important tool in confirming the diagnosis and prognosis for this type of neoplasia.
Journal
|
SOX10 (SRY-Box 10) • YBX1 (Y-Box Binding Protein 1)
1m
Heme Oxygenase-1 Overexpression Promotes Uveal Melanoma Progression and Is Associated with Poor Clinical Outcomes. (PubMed, Antioxidants (Basel))
Our results demonstrated an increased median HO-1 expression in metastasizing UM when compared to nonmetastasizing patients. Overall, our results showed that HO-1 derived CO plays a major role in UM progression and HO-1 protein expression may serve as a potential prognostic and therapeutical factor in UM patients.
Clinical data • Journal
|
HMOX1 (Heme Oxygenase 1)
|
HMOX1 expression • HMOX1 overexpression
1m
Lack of Retinoblastoma Protein Shifts Tumor Metabolism from Glycolysis to OXPHOS and Allows the Use of Alternate Fuels. (PubMed, Cells)
We also demonstrate that modulation of the Rb-regulated transcription factor E2F2 does not result in any of these metabolic perturbations. In conclusion, we demonstrate RB1 or HK1 as critical regulators of the cellular bioenergetic profile and identify the altered tumor metabolism as a potential therapeutic target for cancers lacking functional Rb protein.
Journal
|
RB1 (RB Transcriptional Corepressor 1) • E2F2 (E2F Transcription Factor 2)
|
RB1 mutation
1m
Galectin-3 Is a Natural Binding Ligand of MCAM (CD146, MUC18) in Melanoma Cells and Their Interaction Promotes Melanoma Progression. (PubMed, Biomolecules)
Thus, galectin-3 is a natural binding ligand of MCAM in melanoma, and their interaction activates MCAM and promotes MCAM-mediated melanoma progression. Targeting the galectin-3-MCAM interaction may potentially be a useful therapeutic strategy for melanoma treatment.
Journal
|
MCAM